List of Biologics and Biosimilars

Psoriasis

TNF Blockers

How Does It Work?

Etanercept is a biologic that targets the overactive immune system in psoriasis. Etanercept works by supressing tumor necrosis factor-alpha (TNFa). Useful in psoriasis and psoriatic arthritis.

How Is It Used?

Etanercept is an injectable medication that is administered subcutaneously. This can be home dosed.

  • For plaque psoriasis: 50 mg twice weekly for 3 months, then 50 mg once weekly thereafter
  • For psoriatic arthritis: 50 mg once weekly

Side Effects?

The most common side effects of etanercept include temporary pain and redness around the injection site, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of etanercept, talk your doctor or pharmacist.

Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on etanercept. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on etanercept.

Etanercept and other TNF inhibitory medications should be avoided in patients with or who have a close relative with multiple sclerosis. Etanercept should also be avoided in patients with severe heart failure. Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

Etanercept should be avoided in patients who are immunocompromised or HIV positive.

Interactions?

Some medications that may interact with etanercept include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with etanercept and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

Product Monograph

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Patient Support Program

Etanercept (Enbrel®): https://www.amgen.ca/products/patient-assistance/
Etanercept biosimilar (Erelzi™): Call 1-844-27XPOSE (1-844-279-7673) for information

Brenzys
Harmony patient support program
Phone 1-866-556-5663
https://rheuminfo.com/docs/physician-tools/patient-support-programs/Brenzys_EN.pdf

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
AlbertaBiologics and BiosimilarsEtanerceptEnbrel®NoNo
AlbertaBiologics and BiosimilarsEtanerceptErelzi™Yes – S/A Yes – S/A
AlbertaBiologics and BiosimilarsEtanerceptBrenzys®Yes – S/AYes – S/A
AlbertaBiologics and BiosimilarsEtanerceptRymtiYes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsetanerceptEnbrel®No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  No – S/A requests for psoriatic arthritis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  
British ColumbiaBiologics and BiosimilarsEtanerceptErelzi™Yes - S/AYes – S/A
British ColumbiaBiologics and BiosimilarsEtanerceptBrenzys®Yes - S/AYes – S/A
ManitobaBiologics and BiosimilarsEtanerceptEnbrel®Yes – EDS. Erelzi or Brenzys will be the preferred etanercept option for all etanercept-naïve patients prescribed an etanercept product for psoriasis.Yes – EDS. Erelzi or Brenzys will be the preferred etanercept option for all etanercept-naïve patients prescribed an etanercept product for psoriatic arthritis.
ManitobaBiologics and BiosimilarsEtanerceptErelzi™Yes – EDS  Yes – EDS
ManitobaBiologics and BiosimilarsEtanerceptBrenzys®Yes - EDSYes - EDS
New BrunswickBiologics and BiosimilarsEtanerceptEnbrel®NoNo
New BrunswickBiologics and BiosimilarsEtanerceptErelzi™Yes – S/A Yes – S/A
New BrunswickBiologics and BiosimilarsEtanerceptBrenzys®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsEtanerceptRymtiYes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsEtanerceptEnbrel®NoNo
Newfoundland and LabradorBiologics and BiosimilarsEtanerceptErelzi™Yes – S/A Yes – S/A
Newfoundland and LabradorBiologics and BiosimilarsEtanerceptBrenzys®Yes – S/A Yes – S/A 
NIHBBiologics and BiosimilarsEtanerceptEnbrel®NoYes- Only for clients who received approval for Enbrel before October 2, 2017
NIHBBiologics and BiosimilarsEtanerceptErelzi™NoYes- L/U
NIHBBiologics and BiosimilarsEtanerceptBrenzys®NoYes - L/U
NIHBBiologics and BiosimilarsEtanerceptRymtiNoYes - L/U
Northwest TerritoriesBiologics and BiosimilarsEtanerceptEnbrel®NoYes – L/U
Northwest TerritoriesBiologics and BiosimilarsEtanerceptErelzi™Yes- L/UYes – L/U
Northwest TerritoriesBiologics and BiosimilarsEtanerceptBrenzys®NoYes - L/U
Northwest TerritoriesBiologics and BiosimilarsEtanerceptRymtiNoYes - L/U
Nova ScotiaBiologics and BiosimilarsEtanerceptEnbrel®Yes – EDS; for etanercept-naïve patients whose etanercept therapy is initiated after Nov 1, 2017, a biosimilar will be the product that is approved.  Yes – EDS; for etanercept-naïve patients whose etanercept therapy is initiated after Nov 1, 2017, a biosimilar will be the product that is approved.  
Nova ScotiaBiologics and BiosimilarsEtanerceptErelzi™NoYes – EDS
Nova ScotiaBiologics and BiosimilarsEtanerceptBrenzys®Yes - EDSYes - EDS
Nova ScotiaBiologics and BiosimilarsEtanerceptRymtiYes - EDSYes - EDS
NunavutBiologics and BiosimilarsEtanerceptBrenzys®NoYes - L/U
NunavutBiologics and BiosimilarsEtanerceptEnbrel®NoYes – L/U
NunavutBiologics and BiosimilarsEtanerceptErelzi™Yes- L/UYes – L/U
OntarioBiologics and BiosimilarsEtanerceptBrenzys®Yes – L/U Yes – L/U
OntarioBiologics and BiosimilarsEtanerceptEnbrel®Yes - EAPYes - EAP
OntarioBiologics and BiosimilarsEtanerceptErelzi™Yes – L/U Yes – L/U
OntarioBiologics and BiosimilarsEtanerceptRymtiYes - L/UYes - L/U
Prince Edward IslandBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsEtanerceptErelzi™Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsEtanerceptBrenzys®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/A. If treatment began before August 19, 2020 Yes – S/A. If treatment began before August 19, 2020 
QuebecBiologics and BiosimilarsEtanerceptErelzi™Yes – S/AYes – S/A 
QuebecBiologics and BiosimilarsEtanerceptBrenzys®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsEtanerceptRymtiYes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsEtanerceptEnbrel®NoNo
SaskatchewanBiologics and BiosimilarsEtanerceptErelzi™Yes – EDS Yes – EDS
SaskatchewanBiologics and BiosimilarsEtanerceptBrenzys®Yes – EDSYes – EDS
YukonBiologics and BiosimilarsEtanerceptEnbrel®Yes - EDS ; all new etanercept patients will be covered for Brenzys or ErelziYes – EDS; all new etanercept patients will be covered for Erelzi 
YukonBiologics and BiosimilarsEtanerceptErelzi™Yes - EDSYes – EDS
YukonBiologics and BiosimilarsEtanerceptBrenzys®Yes - EDSYes – EDS
NunavutBiologics and BiosimilarsEtanerceptRymtiNoYes - L/U

How Does It Work?

Adalimumab is a biologic that targets the overactive immune system in psoriasis. Adalimumab works by supressing tumor necrosis factor (TNFa). Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Adalimumab is an injectable medication that is administered subcutaneously. This can be home dosed.

  • For plaque psoriasis: 80 mg as an initial dose, then 40 mg every other week starting one week after initial dose
  • For psoriatic arthritis: 40 mg every other week
  • For plaque psoriasis: 50 mg twice weekly for 3 months, then 50 mg once weekly thereafter
  • For psoriatic arthritis: 50 mg once weekly

Side Effects?

The most common side effects of adalimumab include temporary pain and redness around the injection site, headaches, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of adalimumab, talk your doctor or pharmacist.

Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on adalimumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on adalimumab.

Adalimumab and other TNF inhibitory medications should be avoided in patients with or who have a close relative with multiple sclerosis. Adalimumab should also be avoided in patients with severe heart failure. Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

Interactions?

Some medications that may interact with adalimumab include abatacept (Orencia®), anakinra (Kineret®) and other TNF-blockers such as Enbrel®, Remicade®, Cimzia®, or Simponi®. Adalimumab can potentially affect the speed at which cyclosporine and warfarin are metabolized and their doses may need to be adjusted. For a complete list of medications that may interact with adalimumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

Product Monograph

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have. 

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Patient Support Program

AbbVie Care Support Program
https://abbviecare.ca/

Hadlima
Phone 1-866-556-5663 | https://harmonyorganon.ca/hadlima/en/index.html

Hyrimoz
Phone 1-888-6-SANDOZ (726369) | Email support.continum@sandoz.com

Idacio
Idacio KabiCare patient support program
https://kabicare.ca | Phone 1-888-304-2034| Email info@kabicare.ca

Amgevita
Enliven Services:
Phone: 1-877-936-2735 | Email amgevita@oneenliven.ca
www.amgevita.ca

Hulio
hulio.ca
Phone: 1-844-485-4677 | Email hulio@assistprogram.com

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
AlbertaBiologics and BiosimilarsAdalimumabHumira®NoNo
AlbertaBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
AlbertaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
AlbertaBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/A
AlbertaBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
AlbertaBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/A
AlbertaBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
AlbertaBiologics and BiosimilarsAdalimumabSimlandiYes – S/AYes – S/A
AlbertaBiologics and BiosimilarsAdalimumabYuflymaYes – S/AYes – S/A
British ColumbiaBiologics and BiosimilarsAdalimumabHumira®No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  No – S/A requests for psoriatic arthritis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  
British ColumbiaBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabAbriladaYes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabSimlandiYes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabYuflymaYes - S/AYes - S/A
ManitobaBiologics and BiosimilarsAdalimumabHumira®Yes - EDS. Hadlima, Hyrimoz, Idacio, Amgevita or Idacio will be the preferred adalimumab option for all adalimumab-naïve patients prescribed an adalimumab product for psoriasis.Yes - EDS. Hadlima, Hyrimoz, Idacio, Amgevita or Idacio will be the preferred adalimumab option for all adalimumab-naïve patients prescribed an adalimumab product for psoriatic arthritis.
ManitobaBiologics and BiosimilarsAdalimumabHadlima®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabIdacio®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabAmgevita®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabHulio®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabAbriladaYes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabSimlandiYes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabYuflymaYes - EDSYes - EDS
New BrunswickBiologics and BiosimilarsAdalimumabHumira®NoNo
New BrunswickBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsAdalimumabSimlandiYes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsAdalimumabYuflymaYes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHumira®Yes - S/A All SA requests for coverage of adalimumab for adalimumab- naïve patients will be assessed for the biosimilars of adalimumab only. Patients whose initial Special Authority was received before April 17, 2021 will be eligible for coverage of Humira.Yes - S/A All SA requests for coverage of adalimumab for adalimumab- naïve patients will be assessed for the biosimilars of adalimumab only. Patients whose initial Special Authority was received before April 17, 2021 will be eligible for coverage of Humira.
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabSimlandiYes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabYuflymaYes – S/AYes – S/A
NIHBBiologics and BiosimilarsAdalimumabHumira®Yes- only for clients who received approval for Humira before June 11, 2021Yes- only for clients who received approval for Humira before June 11, 2021
NIHBBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabAbriladaYes – L/UYes – S/A
NIHBBiologics and BiosimilarsAdalimumabSimlandiYes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabYuflymaYes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHumira®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabAbriladaYes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabSimlandiYes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabYuflymaYes - L/UYes - L/U
Nova ScotiaBiologics and BiosimilarsAdalimumabHumira®Yes- only for clients who received approval for Humira before December 15, 2021Yes- only for clients who received approval for Humira before December 15, 2021
Nova ScotiaBiologics and BiosimilarsAdalimumabHadlima®Yes – EDSYes – EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabHyrimoz®Yes – EDSYes – EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabIdacio®Yes – EDSYes – EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabAmgevita®Yes – EDSYes – EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabHulio®Yes – EDSYes – EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabAbriladaYes – EDSYes – EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabSimlandiYes – EDSYes – EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabYuflymaYes – EDSYes – EDS
NunavutBiologics and BiosimilarsAdalimumabAbriladaYes - L/UYes - L/U
NunavutBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsAdalimumabHumira®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabAbriladaYes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabHumira®Yes - EAPYes - EAP
OntarioBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabSimlandiYes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabYuflymaYes - L/UYes - L/U
Prince Edward IslandBiologics and BiosimilarsAdalimumabHumira®Yes - S/AYes - S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabHadlima®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabHyrimoz®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabIdacio®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabHulio®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabSimlandiYes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabYuflymaYes – S/AYes – S/A
QuebecBiologics and BiosimilarsAdalimumabHumira®Yes - S/A. If treatment began before August 19, 2020.Yes - S/A. If treatment began before August 19, 2020.
QuebecBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
QuebecBiologics and BiosimilarsAdalimumabHyrimoz®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsAdalimumabIdacio®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsAdalimumabAmgevita®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsAdalimumabHulio®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
QuebecBiologics and BiosimilarsAdalimumabSimlandiYes – S/AYes – S/A
QuebecBiologics and BiosimilarsAdalimumabYuflymaYes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsAdalimumabHumira®NoNo
SaskatchewanBiologics and BiosimilarsAdalimumabHadlima®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsAdalimumabHyrimoz®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsAdalimumabIdacio®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsAdalimumabAmgevita®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsAdalimumabHulio®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsAdalimumabAbriladaYes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsAdalimumabSimlandiYes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsAdalimumabYuflymaYes – EDSYes – EDS
YukonBiologics and BiosimilarsAdalimumabHumira®Yes - EDSYes - EDS
YukonBiologics and BiosimilarsAdalimumabHadlima®Yes - EDSYes - EDS
YukonBiologics and BiosimilarsAdalimumabHyrimoz®Yes - EDSYes - EDS
YukonBiologics and BiosimilarsAdalimumabIdacio®Yes - EDSYes - EDS
YukonBiologics and BiosimilarsAdalimumabAmgevita®Yes - EDSYes - EDS
YukonBiologics and BiosimilarsAdalimumabHulio®Yes - EDSYes - EDS
YukonBiologics and BiosimilarsAdalimumabAbriladaYes - EDSYes - EDS
YukonBiologics and BiosimilarsAdalimumabSimlandiYes - EDSYes - EDS
YukonBiologics and BiosimilarsAdalimumabYuflymaYes - EDSYes - EDS
NunavutBiologics and BiosimilarsAdalimumabSimlandiYes - L/UYes - L/U
NunavutBiologics and BiosimilarsAdalimumabYuflymaYes - L/UYes - L/U

How Does It Work?

Infliximab is a biologic that targets the overactive immune system in psoriasis. Infliximab works by supressing tumor necrosis factor-alpha (TNFa). Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Infliximab is an injectable medication that is administered intravenously, useful for psoriasis and psoriatic arthritis. Typically this is done in an infusion centre.

  • For plaque psoriasis: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter
  • For psoriatic arthritis: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter

Side Effects?

The most common side effects of infliximab include temporary pain and redness around the infusion site, headaches, nausea, joint pain, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of infliximab, talk your doctor or pharmacist.

Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on infliximab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on infliximab.

Infliximab and other TNF inhibitory medications should be avoided in patients with or who have a close relative with multiple sclerosis. Infliximab should also be avoided in patients with severe heart failure. Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

Interactions?

Some medications that may interact with infliximab include cyclosporine, echinacea, phenytoin, and warfarin. For a complete list of medications that may interact with infliximab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

Product Monograph

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Patient Support Program

Infliximab (Remicade®): https://www.bioadvancemember.ca/en/global/home
Infliximab biosimilar Inflectra®: https://www.pfizer.ca/assistance-programs
Infliximab biosimilar Renflexis®: http://www.merckharmony.ca/

Avsola
Enliven Services
Ph: 1-877-9ENBREL (936-2735) | Email info@oneenliven.ca
www.enbrel.ca; www.avsola.ca

Remsima
CELLTRION CONNECT™ patient support program for Remsima
Interested individuals can find out more about CELLTRION CONNECT™ by visiting www.celltrionconnect.ca/

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
AlbertaBiologics and BiosimilarsInfliximabRemicade®NoNo 
AlbertaBiologics and BiosimilarsInfliximabAvsola®Yes – S/AYes – S/A
AlbertaBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
British ColumbiaBiologics and BiosimilarsInfliximabRemicade®NoNo 
British ColumbiaBiologics and BiosimilarsInfliximabAvsola®Yes – S/AYes – S/A
British ColumbiaBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
ManitobaBiologics and BiosimilarsInfliximabRemicade®Yes – EDS. Inflectra, Renflexis or Avsola will be the preferred infliximab option for all infliximab-naïve patients prescribed an infliximab product.Yes – EDS. Inflectra, Renflexis or Avsola will be the preferred infliximab option for all infliximab-naïve patients prescribed an infliximab product.
ManitobaBiologics and BiosimilarsInfliximabAvsola®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsInfliximabInflectra®Yes – EDSYes – EDS
New BrunswickBiologics and BiosimilarsInfliximabRemicade®NoNo
New BrunswickBiologics and BiosimilarsInfliximabAvsola®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsInfliximabInflectra®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsInfliximabRemicade®Yes – S/A; Inflectra or Renflexis are the preferred infliximab therapy for treatment naïve patients (coverage will only be considered for Remicade in patients stabilized prior to June 1, 2016). No
Newfoundland and LabradorBiologics and BiosimilarsInfliximabAvsola®Yes - S/AYes - SA
Newfoundland and LabradorBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
NIHBBiologics and BiosimilarsInfliximabRemicade®NoNo
NIHBBiologics and BiosimilarsInfliximabAvsola®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsInfliximabInflectra®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsInfliximabRemicade®NoNo
Northwest TerritoriesBiologics and BiosimilarsInfliximabAvsola®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsInfliximabInflectra®Yes – L/UYes – L/U
Nova ScotiaBiologics and BiosimilarsInfliximabRemicade®Yes – S/A. For infliximab naïve patients whose infliximab therapy is initiated after June 1, 2016, an infliximab biosimilar will be the product approved. Yes – S/A. For infliximab naïve patients whose infliximab therapy is initiated after June 1, 2016, an infliximab biosimilar will be the product approved. 
Nova ScotiaBiologics and BiosimilarsInfliximabAvsola®Yes – EDSYes – EDS
Nova ScotiaBiologics and BiosimilarsInfliximabInflectra®Yes – EDSYes – EDS
NunavutBiologics and BiosimilarsInfliximabAvsola®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsInfliximabInflectra®Yes – L/UYes – L/U
NunavutBiologics and BiosimilarsInfliximabOmvyence™NoNo
NunavutBiologics and BiosimilarsInfliximabRemicade®NoNo
NunavutBiologics and BiosimilarsInfliximabRemsima™NoNo
NunavutBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/U
OntarioBiologics and BiosimilarsInfliximabAvsola®Yes – L/UYes – L/U
OntarioBiologics and BiosimilarsInfliximabInflectra®Yes – L/UYes – L/U
OntarioBiologics and BiosimilarsInfliximabOmvyence™NoNo
Prince Edward IslandBiologics and BiosimilarsInfliximabRemicade®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsInfliximabAvsola®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsInfliximabRemicade®Yes – S/A. If treatment began before August 19, 2020 Yes – S/A. If treatment began before August 19, 2020 
QuebecBiologics and BiosimilarsInfliximabAvsola®Yes - S/AYes - S/A
QuebecBiologics and BiosimilarsInfliximabInflectra®Yes - S/AYes - S/A
SaskatchewanBiologics and BiosimilarsInfliximabRemicade®NoNo
SaskatchewanBiologics and BiosimilarsInfliximabAvsola®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsInfliximabInflectra®Yes – EDSYes – EDS
YukonBiologics and BiosimilarsInfliximabRemicade®Yes – EDS; all new infliximab patients will be covered for Inflectra brand only.Yes – EDS; all new infliximab patients will be covered for Inflectra brand only.
YukonBiologics and BiosimilarsInfliximabAvsola®NoNo
YukonBiologics and BiosimilarsInfliximabInflectra®Yes - EDSYes - EDS
AlbertaBiologics and BiosimilarsInfliximabOmvyence™NoNo
AlbertaBiologics and BiosimilarsInfliximabRemsima™NoNo
AlbertaBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
British ColumbiaBiologics and BiosimilarsInfliximabOmvyence™NoNo
British ColumbiaBiologics and BiosimilarsInfliximabRemsima™NoNo
British ColumbiaBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
ManitobaBiologics and BiosimilarsInfliximabOmvyence™NoNo
ManitobaBiologics and BiosimilarsInfliximabRemsima™NoNo
ManitobaBiologics and BiosimilarsInfliximabRenflexis®Yes – EDSYes – EDS
New BrunswickBiologics and BiosimilarsInfliximabOmvyence™NoNo
New BrunswickBiologics and BiosimilarsInfliximabRemsima™NoNo
New BrunswickBiologics and BiosimilarsInfliximabRenflexis®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsInfliximabOmvyence™NoNo
Newfoundland and LabradorBiologics and BiosimilarsInfliximabRemsima™NoNo
Newfoundland and LabradorBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
NIHBBiologics and BiosimilarsInfliximabOmvyence™NoNo
NIHBBiologics and BiosimilarsInfliximabRemsima™NoNo
NIHBBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsInfliximabOmvyence™NoNo
Northwest TerritoriesBiologics and BiosimilarsInfliximabRemsima™NoNo
Northwest TerritoriesBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/U
Nova ScotiaBiologics and BiosimilarsInfliximabOmvyence™NoNo
Nova ScotiaBiologics and BiosimilarsInfliximabRemsima™NoNo
Nova ScotiaBiologics and BiosimilarsInfliximabRenflexis®Yes – EDSYes – EDS
OntarioBiologics and BiosimilarsInfliximabRemicade®Yes - EAPYes - EAP
OntarioBiologics and BiosimilarsInfliximabRemsima™NoNo
OntarioBiologics and BiosimilarsInfliximabRenflexis®Yes – L/UYes – L/U
Prince Edward IslandBiologics and BiosimilarsInfliximabOmvyence™NoNo
Prince Edward IslandBiologics and BiosimilarsInfliximabRemsima™NoNo
Prince Edward IslandBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsInfliximabOmvyence™NoNo
QuebecBiologics and BiosimilarsInfliximabRemsima™NoNo
QuebecBiologics and BiosimilarsInfliximabRenflexis®Yes - S/AYes - S/A
SaskatchewanBiologics and BiosimilarsInfliximabOmvyence™NoNo
SaskatchewanBiologics and BiosimilarsInfliximabRemsima™NoNo
SaskatchewanBiologics and BiosimilarsInfliximabRenflexis®Yes – EDSYes – EDS
YukonBiologics and BiosimilarsInfliximabOmvyence™NoNo
YukonBiologics and BiosimilarsInfliximabRemsima™NoNo
YukonBiologics and BiosimilarsInfliximabRenflexis®Yes - EDSYes - EDS

How Does It Work?

Golimumab is a biologic that targets the overactive immune system in psoriatic arthritis. Golimumab works by supressing tumor necrosis factor-alpha (TNFa).

How Is It Used?

Golimumab is a biologic medication that can be administered either subcutaneously or intravenously.

Side Effects?

The most common side effects of golimumab are an increased risk of infection and a temporary injection site reaction. To obtain a comprehensive list of all known potential side effects of golimumab, talk your doctor or pharmacist.

Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on golimumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on golimumab.

Golimumab should be avoided in patients with severe heart failure.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

Interactions?

Some medications that may interact with golimumab include abatacept, anakinra, baricitinib, belimumab, canakizumab, certolizumab pegol, cladribine, echinacea, infliximab, leflunomide, natalizumab, pimecrolimus, rilonacept, roflumilast, tacrolimus, tocilizumab, tofacitinib, and vedolizumab. For a complete list of medications that may interact with golimumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

Product Monograph

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Patient Support Program

https://www.bioadvancemember.ca/en/global/home 

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
AlbertaBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
British ColumbiaBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
ManitobaBiologics and BiosimilarsGolimumabSimponi®N/AYes – EDS
New BrunswickBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
NIHBBiologics and BiosimilarsGolimumabSimponi®N/AYes – L/U
Northwest TerritoriesBiologics and BiosimilarsGolimumabSimponi®N/AYes – L/U
Nova ScotiaBiologics and BiosimilarsGolimumabSimponi®NoYes – EDS
OntarioBiologics and BiosimilarsGolimumabSimponi®N/AYes - EAP
Prince Edward IslandBiologics and BiosimilarsGolimumabSimponi®NoYes – S/A
QuebecBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
SaskatchewanBiologics and BiosimilarsGolimumabSimponi®NoYes – EDS
YukonBiologics and BiosimilarsGolimumabSimponi®N/AYes – EDS
NunavutBiologics and BiosimilarsGolimumabSimponi®N/AYes – L/U

How Does It Work?

Certolizumab is a biologic that targets the overactive immune system in psoriasis. Certolizumab works by supressing tumor necrosis factor-alpha (TNFa).

Useful in psoriasis and psoriatic arthritis.

How Is It Used?

Certolizumab is an injectable medication that is administered subcutaneously.

  • For plaque psoriasis: 400 mg every 2 weeks
  • For psoriatic arthritis: 400 mg at weeks 0, 2, and 4, followed by 200 mg every 2 weeks

Side Effects?

The most common side effects of certolizumab include joint pain, and an increased risk of  upper respiratory tract infections and urinary tract infections. To obtain a comprehensive list of all known potential side effects of certolizumab, talk your doctor or pharmacist.

Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on certolizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on certolizumab.

Certolizumab should be avoided in patients with moderate to severe heart failure.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

Interactions?

Some medications that may interact with certolizumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with certolizumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

Product Monograph

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Patient Support Program

UCB Cares 1-800-908-5555

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
AlbertaBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – S/A
British ColumbiaBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes - S/A
ManitobaBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – EDS
New BrunswickBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – S/A
NIHBBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – L/U
Northwest TerritoriesBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – L/U
Nova ScotiaBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – EDS
NunavutBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – L/U
OntarioBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – EAP
Prince Edward IslandBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – S/A
QuebecBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – S/A
SaskatchewanBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – EDS
YukonBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – EDS

IL17 Blockers

How Does It Work?

Ixekizumab is a biologic that targets the overactive immune system in psoriasis. Ixekizumab works by supressing interleukin-17A. Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Ixekizumab is an injectable medication that is administered subcutaneously.

  • For plaque psoriasis: 160 mg once, followed by 80 mg at weeks 2, 4, 6, 8, 10 and 12, and then 80 mg every 4 weeks
  • For psoriatic arthritis: 160 mg once, followed by 80 mg every 4 weeks

Side Effects?

The most common side effects of ixekizumab include temporary pain and redness around the injection site, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of ixekizumab, talk your doctor or pharmacist.

Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on ixekizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on ixekizumab.

Ixekizumab should be avoided in patients with currently active or previous history of inflammatory bowel disease.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

Interactions?

Some medications that may interact with ixekizumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with ixekizumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

Product Monograph

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Patient Support Program

Call 1-877-219-8908 for information.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
AlbertaBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
British ColumbiaBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
ManitobaBiologics and BiosimilarsIxekizumabTaltz®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsIxekizumabSiliq™Yes – EDSN/A
New BrunswickBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
NIHBBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/U
Northwest TerritoriesBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/U
Nova ScotiaBiologics and BiosimilarsIxekizumabTaltz®Yes – EDSYes – EDS
OntarioBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes - EAP
Prince Edward IslandBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsIxekizumabTaltz®Yes – EDSYes – EDS
YukonBiologics and BiosimilarsIxekizumabTaltz®Yes - EDSYes - EDS
NunavutBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/U

How Does It Work?

Secukinumab is a biologic that targets the overactive immune system in psoriasis. Secukinumab works by supressing interleukin-17A. Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Secukinumab is an injectable medication that is administered subcutaneously.

  • For plaque psoriasis: 300 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks
  • For psoriatic arthritis: For patients not treated previously by a biological agent – 150 mg (or 300 mg for some patients) once weekly at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks. For those with previous treatment with a biologic agent – 300 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks.

Side Effects?

The most common side effect of secukinumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of secukinumab, talk your doctor or pharmacist.

Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on secukinumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on secukinumab.

Secukinumab should be avoided in patients with currently active or previous history of inflammatory bowel disease.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

Interactions?

Some medications that may interact with secukinumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with secukinumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

Product Monograph

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Patient Support Program

https://www.cosentyx.ca/home/plaque-psoriasis/xpose-your-support-network/

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
NunavutBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UYes – L/U
AlbertaBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
British ColumbiaBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
ManitobaBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes – EDS
New BrunswickBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
NIHBBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UYes – L/U
Northwest TerritoriesBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UYes – L/U
Nova ScotiaBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes - EDS
OntarioBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UYes - EAP
Prince Edward IslandBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes – EDS
YukonBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes – EDS

IL12/23 Blockers

How Does It Work?

Ustekinumab is a biologic that targets the overactive immune system in psoriasis. Ustekinumab works by suppressing interleukin 12 and interleukin 23. Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Ustekinumab is an injectable medication that is administered subcutaneously. Can be home dosed.

  • For plaque psoriasis:
    ≤100 kg: 45 mg at 0 and 4 weeks, and then every 12 weeks thereafter
    >100 kg: 90 mg at 0 and 4 weeks, and then every 12 weeks thereafter
  • For psoriatic arthritis: 45 mg at 0 and 4 weeks, and then every 12 weeks thereafter.

Side Effects?

The most common side effect of ustekinumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of ustekinumab, talk your doctor or pharmacist.

Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on ustekinumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on ustekinumab.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment

Interactions?

Some medications that may interact with ustekinumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with ustekinumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

Product Monograph

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Patient Support Program

https://www.bioadvancemember.ca/en/global/home

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
AlbertaBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
AlbertaBiologics and BiosimilarsUstekinumabWezlanaYes – S/ANo
AlbertaBiologics and BiosimilarsUstekinumabJamtekiYes – S/ANo
British ColumbiaBiologics and BiosimilarsUstekinumabStelara®Yes – S/A until Dec 3 2024No
British ColumbiaBiologics and BiosimilarsUstekinumabJamtekiYes - S/AYes - S/A
ManitobaBiologics and BiosimilarsUstekinumabStelara®Yes – EDSNo
New BrunswickBiologics and BiosimilarsUstekinumabStelara®NoNo
New BrunswickBiologics and BiosimilarsUstekinumabJamtekiYes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsUstekinumabWezlanaYes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
Newfoundland and LabradorBiologics and BiosimilarsUstekinumabJamtekiYes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsUstekinumabWezlanaYes – S/AYes – S/A
NIHBBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
NIHBBiologics and BiosimilarsUstekinumabWezlanaYes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
Northwest TerritoriesBiologics and BiosimilarsUstekinumabWezlanaYes – L/UYes – L/U
Nova ScotiaBiologics and BiosimilarsUstekinumabStelara®Yes - EDSNo
Nova ScotiaBiologics and BiosimilarsUstekinumabJamtekiYes - EDSYes - EDS
Nova ScotiaBiologics and BiosimilarsUstekinumabWezlanaYes - EDSYes - EDS
NunavutBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
NunavutBiologics and BiosimilarsUstekinumabWezlanaYes – L/UYes – L/U
OntarioBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
OntarioBiologics and BiosimilarsUstekinumabJamtekiYes - L/UYes - L/U
OntarioBiologics and BiosimilarsUstekinumabWezlanaYes - L/UYes - L/U
Prince Edward IslandBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
QuebecBiologics and BiosimilarsUstekinumabStelara®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsUstekinumabJamtekiYes – S/AYes – S/A
QuebecBiologics and BiosimilarsUstekinumabWezlanaYes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsUstekinumabStelara®Yes – EDSYes – EDS
YukonBiologics and BiosimilarsUstekinumabStelara®Yes – EDSNo

How Does It Work?

Guselkumab is a biologic that targets the overactive immune system in psoriasis. Guselkumab works by neutralizing interleukin-23.

How Is It Used?

Guselkumab is an injectable medication that is administered subcutaneously by injection. Guselkumab can be used alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) such as methotrexate.

  • For plaque psoriasis: 100 mg at weeks 0 and 4, and then every 8 weeks thereafter
  • For psoriatic arthritis: 100 mg at weeks 0 and 4, and then every 8 weeks thereafter

Side Effects?

The most common side effect of guselkumab is an increased risk of respiratory tract infections. To obtain a comprehensive list of all known potential side effects of guselkumab, talk your doctor or pharmacist.

Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on guselkumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on guselkumab.

Patients should be screened for tuberculosis and infections prior to treatment.

Do not use TREMFYA®/TREMFYA One-Press™ if you are allergic to guselkumab or any of the ingredients in TREMFYA®/TREMFYA OnePress™.

If you think you are allergic, ask your healthcare professional for advice before using TREMFYA®/TREMFYA One-Press™.

Interactions?

For a complete list of medications that may interact with guselkumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

Product Monograph

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Patient Support Program

https://www.bioadvancemember.ca/en/global/home

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
AlbertaBiologics and BiosimilarsGuselkumabTremfya®Yes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsGuselkumabTremfya®NoNo
ManitobaBiologics and BiosimilarsGuselkumabTremfya®Yes - EDSYes - EDS
New BrunswickBiologics and BiosimilarsGuselkumabTremfya®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsGuselkumabTremfya®Yes – S/A Yes – S/A 
NIHBBiologics and BiosimilarsGuselkumabTremfya®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsGuselkumabTremfya®Yes - L/UYes - L/U
Nova ScotiaBiologics and BiosimilarsGuselkumabTremfya®Yes – EDSYes – EDS
OntarioBiologics and BiosimilarsGuselkumabTremfya®Yes - L/UYes - EAP
Prince Edward IslandBiologics and BiosimilarsGuselkumabTremfya®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsGuselkumabTremfya®Yes - S/ANo
SaskatchewanBiologics and BiosimilarsGuselkumabTremfya®Yes - EDSYes - EDS
YukonBiologics and BiosimilarsGuselkumabTremfya®NoNo
NunavutBiologics and BiosimilarsGuselkumabTremfya®Yes - L/UYes - L/U

Abatacept

How Does It Work?

Abatacept is a biologic that targets the overactive immune system in psoriatic arthritis. Abatacept works by supressing the activation of white blood cells called T-cells.

How Is It Used?

Abatacept is a biologic medication that can be administered either subcutaneously or intravenously.

Side Effects?

The most common side effects of abatacept are headache, nausea, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of abatacept, talk your doctor or pharmacist.

Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on abatacept. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on abatacept.

Patients with chronic obstructive pulmonary disease (COPD) are at an increased risk of experience COPD-related adverse events such as cough, shortness of breath, and infection while on abatacept.

Abatacept should be avoided in patients who are immunocompromised or HIV positive.

Interactions?

Some medications that may interact with abatacept include anakinra, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, baricitinib, belimumab, cladribine, echinacea, leflunomide, natalizumab, pimecrolimus, rituximab, roflumilast, tacrolimus, tocilizumab, and tofacitinib. For a complete list of medications that may interact with abatacept and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

Product Monograph

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Patient Support Program

N/A

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
AlbertaBiologics and BiosimilarsAbataceptOrencia®NoNo
British ColumbiaBiologics and BiosimilarsAbataceptOrencia®NoNo
ManitobaBiologics and BiosimilarsAbataceptOrencia®NoNo
New BrunswickBiologics and BiosimilarsAbataceptOrencia®NoNo
Newfoundland and LabradorBiologics and BiosimilarsAbataceptOrencia®NoNo
NIHBBiologics and BiosimilarsAbataceptOrencia®NoNo
Northwest TerritoriesBiologics and BiosimilarsAbataceptOrencia®NoNo
Nova ScotiaBiologics and BiosimilarsAbataceptOrencia®NoNo
NunavutBiologics and BiosimilarsAbataceptOrencia®NoNo
OntarioBiologics and BiosimilarsAbataceptOrencia®N/ANo. EAP may cover in specific clinical circumstances. 
Prince Edward IslandBiologics and BiosimilarsAbataceptOrencia®NoNo
QuebecBiologics and BiosimilarsAbataceptOrencia®NoNo
SaskatchewanBiologics and BiosimilarsAbataceptOrencia®NoNo
YukonBiologics and BiosimilarsAbataceptOrencia®NoNo
This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.